XBIO (Xenetic Bio) Pangali Forward P/E

Simbol resmi perusahaan Xenetic Biosciences, Inc. (XBIO)

Developing oncology platforms requires colossal investment and faces intense pressure from pharma behemoths, where any regulatory delays are critical. Xenetic Biosciences (XBIO) addresses these challenges with XCART, an innovative foundation for creating personalized T-cell therapy. The company's 12-month forward P/E, where 0.00 shows the value of this parameter, illustrates the market valuation of the prospects for drugs combating B-cell lymphomas.

xeneticbio.com - Pangali Forward P/E XBIO (periode 04.07.2022 - 18.11.2026)

Ringkesan rincian data analitis Xenetic Biosciences, Inc. (XBIO)

Ringkesan analitik perusahaan:Xenetic Biosciences, Inc.
Produk merek xeneticbio.com

When assessing the investment attractiveness of Xenetic Biosciences (XBIO), it is essential to weigh the business's market value against its profit generation potential. By analyzing the company's forward P/E ratio, an investor can determine the premium paid for future earnings, which in this case are supported by stable royalties from the use of the patented PolyXen technology, thereby revealing the fair value of capital.

Pesaing Xenetic Biosciences (XBIO)

Pangali Forward P/E ONC|HALO (Halozyme Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (revmed.com)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Bio (BCAX) - Rega marang bathi mangsa ngarep|Personalis Corp - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Systems, Inc. DCTH|Prakiraan rega marang bathi YMAB (Y-mAbs Corp)|Pangali Forward P/E Aura Bio (AURA)|Pangali Forward P/E CADL (Candel Therapeutics Inc.)|ARAY - Prakiraan rega marang bathi|SLS - Rega marang bathi mangsa ngarep|Actuate Therapeutics - Rasio kapitalisasi marang bathi mangsa ngarep|CTOR: Pangali Forward P/E|TuHURA (HURA) - Pangali Forward P/E|TARA (Protara Therapeutics Inc) - Pangali Forward P/E|FATE: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E WHWK|TCRX (TScan) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Champions Oncology, Inc. CSBR|XBIT - Prakiraan rega marang bathi|CEL-SCI - Pangali Forward P/E|OSTX - Pangali Forward P/E|Radiopharm Theranostics Limited (RADX) - Rega marang bathi mangsa ngarep|ARTV - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi ANL|Rega marang bathi mangsa ngarep VERU|Pangali Forward P/E TPST|XLO: Rasio rega marang bathi sing dikarepake|Pangali Forward P/E RENB (Renovaro Inc.)|Mural Bio (MURA) - Rasio prakiraan rega marang bathi|Kairos Pharma Ltd - Pangali Forward P/E|Rasio rega marang bathi sing dikarepake OKUR|CytoMed Therapeutics Limited (GDTC) - Rega marang bathi mangsa ngarep|CRIS - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi APLM|Tharimmune (THAR) - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi ADVB (Advanced Biomed Inc.)|Genprex - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Prakiraan rega marang bathi|SLRX: Prakiraan rega marang bathi|Purple Biotech - Rasio kapitalisasi marang bathi mangsa ngarep|American Oncology Network (AONC) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep BGNE|Prakiraan rega marang bathi CKPT|Rega marang bathi mangsa ngarep ELEV|Pangali Forward P/E ICAD|Pangali Forward P/E Ikena Oncology Inc. (IKNA)|Pangali Forward P/E NTBL (Notable Labs Ltd)|Kapitalisasi marang proyeksi bathi Viracta Therapeutics (VIRX)|MOR: Prakiraan rega marang bathi|NAYA (NAYA Bio) - Rasio rega marang bathi mangsa ngarep|AAPGV: Pangali Forward P/E